DSIP Side Effects: A Neuropeptide Without Established Human Safety
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid neuropeptide identified by Schoenenberger and colleagues in the 1970s. It is marketed for sleep, stress, and recovery without FDA or TGA approval. Published clinical research is limited and historical, and DSIP is not currently a regulator-supported therapeutic.
DSIP is not FDA-approved and lacks controlled human safety data. Not FDA-approved. Not TGA-approved. Marketed for sleep and stress without controlled human safety data. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- DSIP is a neuropeptide identified in the 1970s and marketed today for sleep and stress.
- Not FDA-approved. Not TGA-approved. Not a regulator-supported therapeutic.
- Published clinical research is limited and historical; effects on sleep architecture have been inconsistent.
- Interactions with sedatives, sleep medicines, and other CNS-active drugs are not characterised.
- Compounded or research-grade DSIP is not pharmaceutical-grade.
What is DSIP, and what is it marketed for?
Delta sleep-inducing peptide. DSIP is a neuropeptide first isolated from sleep-inducing fractions of rabbit brain dialysate. Subsequent research described variable effects on sleep architecture, stress, and neuroendocrine measures, with inconsistent results between studies. The mechanism in humans is not well characterised.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Injection-site infection | Cellulitis, abscess from non-sterile compounded product | Compounded peptides are not pharmaceutical-grade |
| Immunogenicity | Allergic reactions to peptide or impurities | Consistent with peptide injection in general |
| Variable trial results | Reported sleep effects have been inconsistent across studies | Published literature shows mixed outcomes |
| Long-term safety | No long-term human safety studies | All available data are short-term |
| Drug interactions | Interactions with sleep medicines, sedatives, and other CNS-active drugs are not characterised | No labelled interaction data |
Taking DSIP alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About DSIP
No. DSIP is not approved by the FDA or TGA for any therapeutic claim.
Published clinical research on DSIP has produced inconsistent results. Some early studies suggested effects on sleep architecture; later work has not consistently replicated the findings. There is no regulator endorsement for sleep use.
Because there is no controlled human safety dataset for current compounded DSIP products, the main concerns are unknown long-term effects, immunogenicity, impurities in compounded product, infection from non-sterile injection, and uncharacterised interactions with other CNS-active medicines.
Yes. Clinicians should know about all peptides, supplements, and sleep medicines you use, especially before surgery, pregnancy, or any change to prescription medicines.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74:1282-1286. Source.
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.